^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    allogeneic K562-GM tumor cell vaccine

    i
    Other names: allogeneic K562-GM tumor cell vaccine
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov)
    P1, N=24, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | N=40 --> 24
    Trial completion • Enrollment change
    |
    CSF2 (Colony stimulating factor 2)
    |
    allogeneic K562-GM tumor cell vaccine
    over2years
    Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Aug 2021 --> Aug 2023
    Trial primary completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    allogeneic K562-GM tumor cell vaccine
    almost4years
    Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Aug 2020 --> Aug 2021
    Trial primary completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    allogeneic K562-GM tumor cell vaccine
    4years
    Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=33, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2020
    Clinical • Trial completion • Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    allogeneic K562-GM tumor cell vaccine
    over4years
    Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas (clinicaltrials.gov)
    P1, N=10, Terminated, National Cancer Institute (NCI) | Trial completion date: Mar 2015 --> Feb 2020 | Completed --> Terminated; Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.
    Clinical • Trial completion date • Trial termination
    |
    IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • allogeneic K562-GM tumor cell vaccine • celecoxib oral • cyclophosphamide intravenous